Enhancement of tumor thermal therapy using gold nanoparticle–assisted tumor necrosis factor-α delivery

Tumor necrosis factor-α (TNF-α) is a potent cytokine with anticancer efficacy that can significantly enhance hyperthermic injury. However, TNF-α is systemically toxic, thereby creating a need for its selective tumor delivery. We used a newly developed nanoparticle delivery system consisting of 33-nm polyethylene glycol–coated colloidal gold nanoparticles (PT-cAu-TNF-α) with incorporated TNF-α payload (several hundred TNF-α molecules per nanoparticle) to maximize tumor damage and minimize systemic exposure to TNF-α. SCK mammary carcinomas grown in A/J mice were treated with 125 or 250 μg/kg PT-cAu-TNF-α alone or followed by local heating at 42.5°C using a water bath for 60 minutes, 4 hours after nanoparticle injection. Increases in tumor growth delay were observed for both PT-cAu-TNF-α alone and heat alone, although the most dramatic effect was found in the combination treatment. Tumor blood flow was significantly suppressed 4 hours after an i.v. injection of free TNF-α or PT-cAu-TNF-α. Tumor perfusion, imaged by contrast enhanced ultrasonography, on days 1 and 5 after treatment revealed perfusion defects after the injection of PT-cAu-TNF-α alone and, in many regions, complete flow inhibition in tumors treated with combination treatment. The combination treatment of SCK tumors in vivo reduced the in vivo/in vitro tumor cell survival to 0.05% immediately following heating and to 0.005% at 18 hours after heating, suggesting vascular damage–mediated tumor cell killing. Thermally induced tumor growth delay was enhanced by pretreatment with TNF-α-coated gold nanoparticles when given i.v. at the proper dosage and timing. [Mol Cancer Ther 2006;5(4):1014–20]

[1]  J. Lyons,et al.  Use of arsenic trioxide as an antivascular and thermosensitizing agent in solid tumors. , 2000, Neoplasia.

[2]  P R Stauffer,et al.  Introduction: Thermal ablation therapy , 2004, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[3]  N. Tsuji,et al.  Recombinant human tumor necrosis factor causes regression in patients with advanced malignancies. , 1994, Oncology.

[4]  H. Park,et al.  Combined treatment of IL-1α and TNF-α potentiates the antitumour effect of hyperthermia , 1996 .

[5]  A. Zhang,et al.  Study of non-uniform nanoparticle liposome extravasation in tumour , 2005, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[6]  A. Corti,et al.  Tumor Vascular Targeting with Tumor Necrosis Factor α and Chemotherapeutic Drugs , 2004 .

[7]  C. Song,et al.  Effect of a Combination of Mild-Temperature Hyperthermia and Nicotinamide on the Radiation Response of Experimental Tumors , 2000, Radiation research.

[8]  Y. Okada,et al.  An investigation of adverse effects caused by the injection of high-dose TNFα-expressing adenovirus vector into established murine melanoma , 2003, Gene Therapy.

[9]  H. Klingler,et al.  Local Intratumoral Tumor Necrosis Factor-α and Systemic IFN-α2b in Patients with Locally Advanced Prostate Cancer , 2001 .

[10]  N. Tsuji,et al.  Enhancement of Blood Stasis and Vascular Permeability in Meth‐A Tumors by Administration of Hyperthermia in Combination with Tumor Necrosis Factor , 1994, Japanese journal of cancer research : Gann.

[11]  P. Couvreur,et al.  Nanoparticles in cancer therapy and diagnosis. , 2002, Advanced drug delivery reviews.

[12]  C. Song,et al.  A Novel Drug to Reduce Tumor Perfusion: Antitumor Effect Alone and with Hyperthermia , 2000, Radiation research.

[13]  A. Benner,et al.  Identification of four genes in endothelial cells whose expression is affected by tumor cells and host immune status--a study in ex vivo-isolated endothelial cells. , 1998, Blood.

[14]  K. Shinohara,et al.  Thermal ablation of prostate diseases: advantages and limitations , 2004, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[15]  E. Wagner,et al.  Tumor-targeted gene delivery of tumor necrosis factor-α induces tumor necrosis and tumor regression without systemic toxicity , 2002, Cancer Gene Therapy.

[16]  M. Morita,et al.  Increased hyperthermic response with prostaglandin E1 in VX2 liver carcinoma in rabbits. , 1991, Journal of the National Cancer Institute.

[17]  M. Dewhirst,et al.  Hyperthermia-regulated immunogene therapy , 2002, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[18]  R. Weichselbaum,et al.  TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Y. Barenholz,et al.  Delivery of cytokines by liposomes. III. Liposome-encapsulated GM-CSF and TNF-alpha show improved pharmacokinetics and biological activity and reduced toxicity in mice. , 1997, Journal of immunotherapy.

[20]  U. Hieber,et al.  Tumor necrosis factor for the treatment of malignancies. , 1994, Oncology.

[21]  M. Dewhirst,et al.  Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. , 2001, Cancer research.

[22]  É. Duguet,et al.  Magnetic nanoparticle design for medical diagnosis and therapy , 2004 .

[23]  J. Bischof,et al.  Pre-treatment inflammation induced by TNF-alpha augments cryosurgical injury on human prostate cancer. , 2004, Cryobiology.

[24]  C. Song Effect of local hyperthermia on blood flow and microenvironment: a review. , 1984, Cancer research.

[25]  John C Bischof,et al.  Sensitization of thermotolerant SCK cells to hyperthermia and freezing with reduction of intracellular pH: Implications for cryosurgery , 2003, Journal of surgical oncology.

[26]  R. Gillies,et al.  Microenvironmental and cellular consequences of altered blood flow in tumours. , 2003, The British journal of radiology.

[27]  Lawrence Tamarkin,et al.  Colloidal Gold: A Novel Nanoparticle Vector for Tumor Directed Drug Delivery , 2004, Drug delivery.

[28]  A. Eggermont,et al.  Biodistribution and tumor localization of stealth liposomal tumor necrosis factor‐α in soft tissue sarcoma bearing rats , 1998, International journal of cancer.

[29]  C. Song,et al.  Arsenic trioxide induces selective tumour vascular damage via oxidative stress and increases thermosensitivity of tumours , 2003, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[30]  E. A. Havell,et al.  The antitumor function of tumor necrosis factor (TNF) II. Analysis of the role of endogenous TNF in endotoxin-induced hemorrhagic necrosis and regression of an established sarcoma , 1988, The Journal of experimental medicine.

[31]  G. Hahn,et al.  Mechanism of Antitumor Activity of Tumor Necrosis Factor α With Hyperthermia in a Tumor Necrosis Factor α-Resistant Tumor , 1990 .

[32]  M. Horsman,et al.  Combination of vascular targeting agents with thermal or radiation therapy. , 2002, International journal of radiation oncology, biology, physics.

[33]  N. Tsuji,et al.  Endogenous tumour necrosis factor regulates heat-inducible heat shock protein 72 synthesis. , 1998, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[34]  J. Trachtenberg,et al.  Interstitial microwave thermal therapy and its application to the treatment of recurrent prostate cancer , 2004, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[35]  W. Fiers,et al.  In vivo anti‐tumour activity of recombinant human and murine TNF, alone and in combination with murine IFN‐γ, on a syngeneic murine melanoma , 1986, International journal of cancer.

[36]  Kullervo Hynynen,et al.  MR imaging-controlled focused ultrasound ablation: a noninvasive image-guided surgery. , 2005, Magnetic resonance imaging clinics of North America.